Camlin Fine

  • Market Cap: Small Cap
  • Industry: Specialty Chemicals
  • ISIN: INE052I01032
  • NSEID: CAMLINFINE
  • BSEID: 532834
INR
151.00
-4.2 (-2.71%)
BSENSE

Dec 05

BSE+NSE Vol: 1.03 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.03 lacs (11.88%) Volume

Shareholding (Dec 2025)

FII

2.12%

Held by 50 FIIs

DII

0.71%

Held by 6 DIIs

Promoter

49.08%

how big is Camlin Fine?

06-Jun-2025

As of October 2023, Camlin Fine Sciences Ltd has a market capitalization of 4,852.00 Cr, categorizing it as a Small Cap company, with recent net sales of 1,687.30 Cr and a net profit of -139.04 Cr over the last four quarters. Shareholder's funds are 864.75 Cr, and total assets amount to 1,911.22 Cr as of March 2024.

Market Cap: Camlin Fine Sciences Ltd has a market capitalization of 4,852.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Mar'25, Dec'24, Sep'24, and Jun'24, is 1,687.30 Cr. The sum of Net Profit for the same quarters is -139.04 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 864.75 Cr, and Total Assets amount to 1,911.22 Cr.

Read More

Who are in the management team of Camlin Fine?

06-Jun-2025

As of March 2023, the management team of Camlin Fine includes Ashish S Dandekar (Chairman & Managing Director), Nirmal V Momaya (Managing Director), and several directors and independent directors, totaling 11 key members who guide the company's governance and strategy.

As of March 2023, the management team of Camlin Fine includes the following members:<BR><BR>1. Ashish S Dandekar - Chairman & Managing Director<BR>2. Nirmal V Momaya - Managing Director<BR>3. Anagha S Dandekar - Director<BR>4. Arujun S Dukane - Executive Director (Technical)<BR>5. Amol Shah - Independent Director<BR>6. Sutapa Banerjee - Independent Director<BR>7. Mahabaleshwar G Palekar - Independent Director<BR>8. Harsha Raghavan - Director<BR>9. Conrad D Souza - Independent Director<BR>10. Pradip M. Kanakia - Independent Director<BR>11. Rahul Sawale - Vice President & Company Secretary<BR><BR>This diverse team encompasses various roles, including executive, independent, and director positions, contributing to the company's governance and strategic direction.

Read More

What does Camlin Fine do?

06-Jun-2025

Camlin Fine Sciences Ltd is a small-cap company in the specialty chemicals industry, originally established in 1993. As of March 2025, it reported net sales of 437 Cr and a net profit of -1 Cr, with a market cap of Rs 4,933 Cr.

Overview: <BR>Camlin Fine Sciences Ltd operates in the specialty chemicals industry and is categorized as a small-cap company.<BR><BR>History: <BR>The company was originally incorporated on November 30, 1993, as Camlicon Consultants Private Limited. It underwent a name change to Camlin Fine Chemicals Private Limited on June 1, 2006, following the demerger of the Fine Chemicals Division from Camlin Limited, effective July 1, 2006. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 437 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 4,933 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 138.00 <BR>Industry P/E: 47 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.54 <BR>Return on Equity: 3.83% <BR>Price to Book: 5.28 <BR><BR>Contact Details: <BR>Address: Plot No F/11 & F/12 WICEL, Central Road Andheri(East) Mumbai Maharashtra : 400093 <BR>Tel: 91-22-67001000 <BR>Email: secretarial@camlinfs.com <BR>Website: http://www.camlinfs.com

Read More

Has Camlin Fine declared dividend?

06-Jun-2025

Yes, Camlin Fine Sciences Ltd has declared a dividend of 45% (0.45 per share) with an ex-date of July 28, 2016. However, the current dividend yield is 0%, despite significant price appreciation over the past five years.

Camlin Fine Sciences Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 45%<BR>- Amount per share: 0.45<BR>- Ex-date: 28 Jul 16<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was 121.16%, with a dividend return of 0%, resulting in a total return of 121.16%.<BR><BR>In the 1 year period, the price return was 181.64%, with a dividend return of 0%, resulting in a total return of 181.64%.<BR><BR>In the 2 years period, the price return was 58.52%, with a dividend return of 0%, resulting in a total return of 58.52%.<BR><BR>In the 3 years period, the price return was 132.74%, with a dividend return of 0%, resulting in a total return of 132.74%.<BR><BR>In the 4 years period, the price return was 51.6%, with a dividend return of 0%, resulting in a total return of 51.6%.<BR><BR>In the 5 years period, the price return was 518.24%, with a dividend return of 0%, resulting in a total return of 518.24%.<BR><BR>Overall, while Camlin Fine has declared a dividend in the past, the current dividend yield is 0%. However, the total returns over various periods demonstrate significant price appreciation, particularly over the 5-year period.

Read More

Who are the peers of the Camlin Fine?

03-Jun-2025

Camlin Fine's peers include Pidilite Industries, SRF, Gujarat Fluoroch, Deepak Nitrite, Himadri Special, Rossari Biotech, Vishnu Chemicals, S H Kelkar & Co., Nocil, and Bhansali Engineering. Camlin Fine has below average management risk, growth, and capital structure compared to its peers, with a notable 1-year return of 163.83%.

Peers: The peers of Camlin Fine are Pidilite Inds., SRF, Gujarat Fluoroch, Deepak Nitrite, Himadri Special, Rossari Biotech, Vishnu Chemicals, S H Kelkar & Co., Nocil, and Bhansali Engg.<BR><BR>Quality Snapshot: Excellent management risk is observed at Deepak Nitrite, Pidilite Inds., Rossari Biotech, and SRF, while Good management risk is found at Vishnu Chemicals and Himadri Special. Average management risk is present at Gujarat Fluoroch, S H Kelkar & Co., and Nocil, while Camlin Fine has Below Average management risk. For Growth, Excellent growth is seen at Himadri Special, while Average growth is noted at Pidilite Inds., Rossari Biotech, and SRF. Below Average growth is found at Gujarat Fluoroch, Deepak Nitrite, S H Kelkar & Co., and Nocil, while Camlin Fine has Below Average growth. In terms of Capital Structure, Excellent capital structure is noted at Pidilite Inds., Deepak Nitrite, and Rossari Biotech, while Good capital structure is observed at Himadri Special, Gujarat Fluoroch, and S H Kelkar & Co. Camlin Fine has Below Average capital structure.<BR><BR>Return Snapshot: Himadri Special has the highest 1-year return at 40.96%, while Deepak Nitrite has the lowest at -9.60%. Camlin Fine's 1-year return is significantly higher at 163.83%. Additionally, the peers with negative six-month returns include Deepak Nitrite, Nocil, and Rossari Biotech.

Read More

Who are the top shareholders of the Camlin Fine?

17-Jul-2025

The top shareholders of Camlin Fine include promoters with the largest individual holding by Ashish Subhash Dandekar at 10.52%, mutual funds at 3.38%, foreign institutional investors at 2.88%, and individual investors collectively owning 30.98%, with Nirmal Vinod Momaya as the highest public shareholder at 1.92%.

The top shareholders of Camlin Fine include the promoters, who hold the majority of the shares. Among them, Ashish Subhash Dandekar has the highest individual holding at 10.52%. Additionally, mutual funds collectively hold 3.38% of the shares through six schemes, while foreign institutional investors (FIIs) hold 2.88% through 48 different entities. The highest public shareholder is Nirmal Vinod Momaya, who holds 1.92%. Individual investors collectively own 30.98% of the company.

Read More

When is the next results date for Camlin Fine?

04-Nov-2025

The next results date for Camlin Fine is 10 November 2025.

The next results date for Camlin Fine is scheduled for 10 November 2025.

Read More

Are Camlin Fine latest results good or bad?

11-Nov-2025

Camlin Fine Sciences' latest results are concerning, showing a 10.19% revenue growth but a consolidated net loss of ₹14.38 crores for the second consecutive quarter, alongside declining operating margins and weak return on equity, indicating significant operational challenges.

Camlin Fine Sciences has reported results that indicate a troubling performance overall. While the company achieved a notable revenue growth of 10.19% year-on-year, reaching its highest quarterly revenue of ₹459.83 crores, this positive aspect is overshadowed by significant operational challenges.<BR><BR>The company recorded a consolidated net loss of ₹14.38 crores for the second consecutive quarter, which raises concerns about its profitability. This loss, although slightly improved from the previous quarter's loss, reflects ongoing difficulties in translating revenue growth into profit. Additionally, the operating margin has sharply declined to 7.27%, down from 12.34% in the same quarter last year, indicating severe margin compression.<BR><BR>Furthermore, the return on equity (ROE) stands at a weak 5.90%, highlighting poor capital efficiency compared to industry peers. The company's high debt burden, with a debt-to-EBITDA ratio of 4.20x, adds to the financial strain.<BR><BR>In summary, while revenue growth is a positive sign, the persistent losses, declining margins, and weak capital efficiency suggest that the latest results are more negative than positive, raising serious concerns about the company's operational health and strategic direction.

Read More

Should I buy, sell or hold Camlin Fine?

12-Nov-2025

How has been the historical performance of Camlin Fine?

12-Nov-2025

Camlin Fine's historical performance has been mixed, with net sales increasing to 1,666.53 Cr in Mar'25 but a significant decline in profitability, resulting in a net loss of -139.05 Cr. While total assets grew, cash flow from operations decreased, indicating inconsistent financial health.

Answer:<BR>The historical performance of Camlin Fine shows a mixed trend over the years, with significant fluctuations in key financial metrics.<BR><BR>Breakdown:<BR>Camlin Fine's net sales increased from 1,412.09 Cr in Mar'22 to 1,666.53 Cr in Mar'25, although it peaked at 1,681.56 Cr in Mar'23. Total operating income followed a similar pattern, reaching 1,666.53 Cr in Mar'25. However, total expenditure also rose, reaching 1,458.41 Cr in Mar'25, up from 1,259.29 Cr in Mar'22. Operating profit (PBDIT) showed some improvement, increasing to 222.57 Cr in Mar'25 from 185.83 Cr in Mar'22, but profit before tax declined significantly to 49.03 Cr in Mar'25 from 94.11 Cr in Mar'22. The net profit turned negative in Mar'25 at -139.05 Cr, down from 60.68 Cr in Mar'22. The company's total assets increased to 1,958.75 Cr in Mar'25 from 1,763.70 Cr in Mar'22, while total liabilities also rose to 1,958.75 Cr in Mar'25 from 1,763.70 Cr in Mar'22. Cash flow from operating activities decreased to 26.00 Cr in Mar'25 from 145.00 Cr in Mar'22, and the closing cash and cash equivalents improved to 104.00 Cr in Mar'25 from 107.00 Cr in Mar'22. Overall, while revenues have shown growth, profitability has been inconsistent, leading to a negative net profit in the latest fiscal year.

Read More

Is Camlin Fine overvalued or undervalued?

26-Nov-2025

As of November 25, 2025, Camlin Fine's valuation has shifted from attractive to fair, indicating it is overvalued with a PE ratio of 327.96 and an EV to EBITDA of 19.86, especially when compared to peers like Solar Industries and Godrej Industries.

As of 25 November 2025, the valuation grade for Camlin Fine has moved from attractive to fair. Based on the analysis, the company appears to be overvalued. Key ratios indicate this, with a PE ratio of 327.96, an EV to EBITDA of 19.86, and a ROE of only 0.98%. <BR><BR>In comparison to its peers, Camlin Fine's valuation metrics stand out unfavorably; for instance, Solar Industries has a PE of 90.94 and an EV to EBITDA of 55.97, while Godrej Industries, which is rated attractive, has a PE of 35.73 and an EV to EBITDA of 39.89. Additionally, despite a strong performance year-to-date with a return of 19.77% compared to the Sensex's 8.25%, the long-term outlook shows a decline over three years, further supporting the notion that Camlin Fine is currently overvalued.

Read More

Is Camlin Fine technically bullish or bearish?

04-Dec-2025

As of December 3, 2025, Camlin Fine's technical trend has shifted to a moderate bearish stance, driven by bearish momentum in the MACD, confirming moving averages, and Bollinger Bands, despite mixed signals from the KST.

As of 3 December 2025, the technical trend for Camlin Fine has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the weekly MACD showing bearish momentum, daily moving averages confirming a bearish trend, and Bollinger Bands indicating bearish conditions on both weekly and monthly time frames. The KST presents a mixed signal with a bearish weekly reading and a bullish monthly reading, but overall, the prevailing bearish indicators suggest a downward pressure on the stock.

Read More

Why is Camlin Fine falling/rising?

04-Dec-2025

As of 04-Dec, Camlin Fine Sciences Ltd's stock price is declining, currently at 156.35, reflecting a 1.36% decrease. The stock has underperformed its sector and has seen a significant drop of 20.39% over the past month, driven by weak fundamentals and reduced investor interest.

As of 04-Dec, Camlin Fine Sciences Ltd's stock price is falling, currently at 156.35, which reflects a decrease of 2.15 or 1.36%. The stock has been on a downward trend, having underperformed its sector by 1.15% today and experiencing a consecutive fall over the last four days, resulting in a total decline of 5.18% during this period. Additionally, the stock has touched an intraday low of Rs 155, marking a decrease of 2.21%.<BR><BR>The stock's performance over the past week shows a decline of 4.58%, while the broader market, represented by the Sensex, has only decreased by 0.53%. Over the past month, Camlin Fine has seen a significant drop of 20.39%, contrasting sharply with the Sensex's increase of 2.16%. Furthermore, the stock is trading below its moving averages across various time frames, indicating a bearish trend.<BR><BR>Investor participation has also decreased, with delivery volume falling by 61.22% compared to the five-day average, suggesting reduced interest from retail investors. Although institutional investors have slightly increased their stake by 0.56% over the previous quarter, the overall sentiment remains negative due to weak long-term fundamentals, including a -2.03% CAGR growth in operating profits over the last five years and a high Debt to EBITDA ratio of 3.61 times.<BR><BR>The company's recent financial results have also contributed to the decline, with a significant drop in profit before tax and net profit, indicating underlying issues that may concern investors. Overall, these factors collectively explain the current downward movement in Camlin Fine's stock price.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Weak Long Term Fundamental Strength with a -2.03% CAGR growth in Operating Profits over the last 5 years

  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.61 times
  • The company has been able to generate a Return on Equity (avg) of 5.57% signifying low profitability per unit of shareholders funds
2

Negative results in Sep 25

stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Specialty Chemicals

stock-summary
Market cap

INR 2,839 Cr (Small Cap)

stock-summary
P/E

337.00

stock-summary
Industry P/E

40

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.58

stock-summary
Return on Equity

0.98%

stock-summary
Price to Book

3.30

Revenue and Profits:
Net Sales:
460 Cr
(Quarterly Results - Sep 2025)
Net Profit:
-14 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-25.8%
0%
-25.8%
6 Months
-40.36%
0%
-40.36%
1 Year
26.58%
0%
26.58%
2 Years
15.43%
0%
15.43%
3 Years
-0.8%
0%
-0.8%
4 Years
10.79%
0%
10.79%
5 Years
25.35%
0%
25.35%

Latest dividend: 0.44999999999999996 per share ex-dividend date: Jul-28-2016

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
News

Is Camlin Fine technically bullish or bearish?

Recent Technical Trend Shift

As of 3 December 2025, Camlin Fine’s technical trend has shifted from mildly bearish to outright bearish. This change reflects growing downward momentum in the stock’s price action, signalling increased selling pressure. The transition is significant as it marks a deterioration in the stock’s technical health, which traders and investors closely monitor for timing entry and exit points.

Key Technical Indicators Paint a Bearish Picture

Examining the Moving Average Convergence Divergence (MACD), a widely used momentum indicator, reveals a bearish stance on the weekly chart and a mildly bearish reading on the monthly chart. This suggests that while short-term momentum is clearly negative, the longer-term trend is only s...

Read More
Announcements stock-summary

Outcome Of The Meeting Of The Securities Issue And Allotment Committee Of The Board Of Directors Of The Company

30-Nov-2025 | Source : BSE

Enclosed.

Announcement under Regulation 30 (LODR)-Updates on Acquisition

30-Nov-2025 | Source : BSE

Update on Acquisition.

Announcement under Regulation 30 (LODR)-Allotment

30-Nov-2025 | Source : BSE

Allotment of equity shares of the Company pursuant to Preferential Issue.

Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Camlin Fine Sciences Ltd has declared 45% dividend, ex-date: 28 Jul 16

stock-summary
SPLITS

Camlin Fine Sciences Ltd has announced 1:2 stock split, ex-date: 04 Sep 14

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

Camlin Fine Sciences Ltd has announced 5:41 rights issue, ex-date: 08 Jan 25

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
9.18%
EBIT Growth (5y)
-2.03%
EBIT to Interest (avg)
1.80
Debt to EBITDA (avg)
4.21
Net Debt to Equity (avg)
0.58
Sales to Capital Employed (avg)
1.04
Tax Ratio
59.89%
Dividend Payout Ratio
0
Pledged Shares
10.84%
Institutional Holding
7.59%
ROCE (avg)
7.86%
ROE (avg)
5.57%
Valuation key factors
Factor
Value
P/E Ratio
337
Industry P/E
40
Price to Book Value
3.30
EV to EBIT
34.17
EV to EBITDA
20.35
EV to Capital Employed
2.46
EV to Sales
1.97
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
7.21%
ROE (Latest)
0.98%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

10.8385

Mutual Funds

Held by 5 Schemes (4.77%)

FIIs

Held by 50 FIIs (2.12%)

Promoter with highest holding

Ashish Subhash Dandekar (10.52%)

Highest Public shareholder

Franklin India Opportunites Fund (2.04%)

Individual Investors Holdings

29.2%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 10.19% vs 2.82% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 85.65% vs -417.18% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "459.83",
          "val2": "417.32",
          "chgp": "10.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "33.42",
          "val2": "51.49",
          "chgp": "-35.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "18.91",
          "val2": "26.32",
          "chgp": "-28.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-8.95",
          "val2": "-162.79",
          "chgp": "94.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.38",
          "val2": "-100.23",
          "chgp": "85.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "7.27%",
          "val2": "12.34%",
          "chgp": "-5.07%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 10.68% vs -3.31% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 81.86% vs -3,403.66% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "883.38",
          "val2": "798.17",
          "chgp": "10.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "52.45",
          "val2": "90.67",
          "chgp": "-42.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "34.74",
          "val2": "49.59",
          "chgp": "-29.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-15.37",
          "val2": "-179.21",
          "chgp": "91.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.34",
          "val2": "-134.19",
          "chgp": "81.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "5.94%",
          "val2": "11.36%",
          "chgp": "-5.42%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 1.47% vs -3.47% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is -785.60% vs -136.38% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,229.19",
          "val2": "1,211.37",
          "chgp": "1.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "148.43",
          "val2": "87.17",
          "chgp": "70.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "83.66",
          "val2": "44.14",
          "chgp": "89.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-188.23",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-138.33",
          "val2": "-15.62",
          "chgp": "-785.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "12.08%",
          "val2": "7.20%",
          "chgp": "4.88%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 14.62% vs -13.54% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -49.92% vs -277.99% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,666.53",
          "val2": "1,453.91",
          "chgp": "14.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "208.12",
          "val2": "159.70",
          "chgp": "30.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "99.88",
          "val2": "60.30",
          "chgp": "65.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-217.34",
          "val2": "-157.83",
          "chgp": "-37.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-139.05",
          "val2": "-92.75",
          "chgp": "-49.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "12.49%",
          "val2": "10.98%",
          "chgp": "1.51%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoYstock-summary
Sep'25
Sep'24
Change(%)
Net Sales
459.83
417.32
10.19%
Operating Profit (PBDIT) excl Other Income
33.42
51.49
-35.09%
Interest
18.91
26.32
-28.15%
Exceptional Items
-8.95
-162.79
94.50%
Consolidate Net Profit
-14.38
-100.23
85.65%
Operating Profit Margin (Excl OI)
7.27%
12.34%
-5.07%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in quarter ended Sep 2025 is 10.19% vs 2.82% in Sep 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 85.65% vs -417.18% in Sep 2024

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary
Sep'25
Sep'24
Change(%)
Net Sales
883.38
798.17
10.68%
Operating Profit (PBDIT) excl Other Income
52.45
90.67
-42.15%
Interest
34.74
49.59
-29.95%
Exceptional Items
-15.37
-179.21
91.42%
Consolidate Net Profit
-24.34
-134.19
81.86%
Operating Profit Margin (Excl OI)
5.94%
11.36%
-5.42%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 10.68% vs -3.31% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2025 is 81.86% vs -3,403.66% in Sep 2024

Nine Monthly Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1,229.19
1,211.37
1.47%
Operating Profit (PBDIT) excl Other Income
148.43
87.17
70.28%
Interest
83.66
44.14
89.53%
Exceptional Items
-188.23
0.00
Consolidate Net Profit
-138.33
-15.62
-785.60%
Operating Profit Margin (Excl OI)
12.08%
7.20%
4.88%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is 1.47% vs -3.47% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2024 is -785.60% vs -136.38% in Dec 2023

Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
1,666.53
1,453.91
14.62%
Operating Profit (PBDIT) excl Other Income
208.12
159.70
30.32%
Interest
99.88
60.30
65.64%
Exceptional Items
-217.34
-157.83
-37.71%
Consolidate Net Profit
-139.05
-92.75
-49.92%
Operating Profit Margin (Excl OI)
12.49%
10.98%
1.51%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 14.62% vs -13.54% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is -49.92% vs -277.99% in Mar 2024

stock-summaryCompany CV
About Camlin Fine Sciences Ltd stock-summary
stock-summary
Camlin Fine Sciences Ltd
Small Cap
Specialty Chemicals
Camlin Fine Sciences Limited was originally incorporated on November 30, 1993 as a Private Limited Company with the name of 'Camlicon Consultants Private Limited'. On June 1, 2006, the Company name was changed from Camlicon Consultants Private Limited to Camlin Fine Chemicals Private Limited. As per the Scheme of Arrangement, the Fine Chemicals Division of Camlin Limited got demerged and transferred to the Company effective from July 01, 2006.
Company Coordinates stock-summary
Company Details
Plot No F/11 & F/12 WICEL, Central Road Andheri(East) Mumbai Maharashtra : 400093
stock-summary
Tel: 91-22-67001000
stock-summary
secretarial@camlinfs.com
Registrar Details
Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai